The expiration date is a potency guarantee, not a safety date

There is a date printed on nearly every medicine container in the country, and it is read wrong almost everywhere. It is not a warning, it is not a countdown, and it is not a statement about what the medicine turns into. It is a promise about a specific moment — the moment you use the drug — and the things promised are written into the regulation in a fixed order: “identity, strength, quality, and purity at the time of use.”

That sentence is 21 CFR 211.137(a), and every word in it is load-bearing. This page is about what the date actually guarantees, what it is built on, and — the part that decides most arguments — what the rule that creates it does not say.

The four standards, and the moment they attach to

The opening clause of § 211.137 reads: “To assure that a drug product meets applicable standards of identity, strength, quality, and purity at the time of use, it shall bear an expiration date determined by appropriate stability testing described in § 211.166.”

Four standards, and the section does not define them further — it fixes them as the set the date guarantees, in that order. Identity: the product is what the label says it is. Strength: it contains what it says it contains, which is the standard the potency argument is usually about. Quality and purity complete the set. What matters for reading the date is not any one of them but the phrase that closes the clause.

“At the time of use.” Not the time of purchase. Not the time of manufacture. The standards are anchored to the moment the drug is taken, which means a bottle used on its last day is covered by the same promise as one used on its first — and, read the other way, that the promise is about use, not about purchase. A product bought today and finished two years from now is guaranteed for the whole of that period. What it is not guaranteed for is any use after the date.

The date, in other words, is the outer edge of a tested guarantee, and the guarantee is expressed in terms of what the product is — not what it might become.

What the date is built on: testing, not the calendar

The date does not come from a convention, a round number, or a manufacturer’s marketing calendar. Section 211.137(a) says it is “determined by appropriate stability testing described in § 211.166,” and § 211.166 is where the testing program lives.

The program is a written one, and its results “shall be used in determining appropriate storage conditions and expiration dates.” Four of its requirements are worth reading slowly:

• Sample size and test intervals “based on statistical criteria for each attribute examined” — the testing plan is built per attribute, on statistics, not per product category.
• “Reliable, meaningful, and specific test methods” — the methods themselves are regulated.
• Testing “in the same container-closure system as that in which the drug product is marketed.” The date was determined for the drug in its own bottle, not for the drug in general. The container is part of what was tested.
• Testing of products for reconstitution “as directed in the labeling as well as after they are reconstituted.” The mixed form is tested in its own right.

Paragraph (b) adds the part that explains why some dates look provisional: accelerated studies — testing under stress conditions — “may be used to support tentative expiration dates provided full shelf life studies are not available and are being conducted.” Where an accelerated study projects beyond what the shelf-life data actually supports, testing must continue “until the tentative expiration date is verified or the appropriate expiration date determined.” A date can begin as a projection, but the rule does not let it stay one.

The storage conditions on the label are part of the guarantee

Paragraph (b) of § 211.137 is one sentence and it is easy to skim past: “Expiration dates shall be related to any storage conditions stated on the labeling, as determined by stability studies described in § 211.166.”

The date and the storage instruction are not two independent pieces of information. The date is related to the stated storage conditions — the guarantee was tested under them. This is why “store at room temperature” sits on the label as a regulatory matter and not as a suggestion: it is one of the conditions the date was determined against.

Where the date has to appear

Section 211.137(d) sends the location question to 21 CFR 201.17, and the answer is more specific than most people expect:

• The date appears on the immediate container — the bottle, the blister — and also on the outer package, if there is one, unless it is easily legible through that outer package.
• One exception: when single-dose containers are packed in individual cartons, the date may appear on the individual carton instead of the immediate product container.

So the box is a second location, not the only one. Throw the box away and the bottle still carries the date, because the rule requires it to be on the container itself.

The reconstitution rule: the most useful paragraph in the section

Paragraph (c): “If the drug product is to be reconstituted at the time of dispensing, its labeling shall bear expiration information for both the reconstituted and unreconstituted drug products.”

This is the one place in the section where the rule anticipates a second, shorter clock starting in your home. The powder’s date is not the liquid’s date. A product that is stable for years as a powder and stable for ten days as a suspension is required to say both — and the label you get from the pharmacy is doing exactly that when it carries a “discard after” date that is far closer than the one on the bottle.

What the regulation does not say

Read the whole section — all eight paragraphs — and look for the claim everyone thinks is in there. There is no statement that an expired drug is dangerous. There is no statement that it is safe. There is no prohibition on using one, no possession rule, and no decay curve. There is no milligram-per-month figure, because the date is not built on a universal rate of decline; it is built on product-specific stability testing, which is the whole point of § 211.166.

The two popular positions — expired medicine turns toxic and expiration dates are a marketing invention — are both claims the regulation does not make. What it makes is a guarantee with an end point. After the end point, the manufacturer’s tested promise simply stops applying: the product was tested to meet four standards at the time of use, up to a date determined by data, and beyond that date there is no promise to read either way.

That is a narrower answer than most people want, and it is the answer the text supports.

The exemptions, and one regulatory fossil

The section exempts four situations, and they are worth knowing because a missing date is not always an oversight:

• Homeopathic drug products are exempt outright, at (e).
• Allergenic extracts labeled “No U.S. Standard of Potency” are exempt, at (f) — the label says it, and the exemption is written into the rule.
• New drug products for investigational use are exempt, at (g), provided they meet appropriate standards or specifications demonstrated by stability studies during their use in clinical investigations — and if they are reconstituted at dispensing, the reconstituted product still carries expiration information.
• The OTC carve-out at (h) is the interesting one. It provides that, “pending consideration of a proposed exemption, published in the Federal Register of September 29, 1978,” the section’s requirements “shall not be enforced for human OTC drug products if their labeling does not bear dosage limitations and they are stable for at least 3 years as supported by appropriate stability data.”

Read (h) slowly, because it is three things at once. It is an enforcement provision, not a repeal — the requirement still stands, and FDA is declining to enforce it against a defined set of products. It is conditional — the product’s labeling must bear no dosage limitations at all, and the product must have at least three years of stability data behind it. And it is a fossil: the proposed exemption it defers to was published on September 29, 1978 — the same day as the rule itself — and the codified text still says “pending” nearly half a century later. The section’s source note confirms the provenance: published at 43 Fed. Reg. 45077, amended in 1981, amended again in 1995, and the “pending” sentence has survived all three.

The “no dosage limitations” condition is also narrower than it first appears. A dosage limitation is a limit on how much to take, printed on the label — and the required liver warning for acetaminophen products states exactly that, a maximum number of daily dosage units in 24 hours as “the maximum daily amount” (21 CFR 201.326(a)(1)(iii)(A)). Read plainly, a product carrying such a statement bears a dosage limitation and is outside the carve-out, fully subject to the section. Most OTC medicine prints its limits in its Directions; the carve-out is for the products that do not.

What this means when you are holding the bottle

The practical reading of the section, in the order a reader can use it:

• The date is the end of a tested guarantee, not the start of a hazard — and also not permission to keep using a product nobody has made a promise about. Both of those are claims the regulation declines to make.
• The storage instruction is part of the promise. The date was determined against the storage conditions on the label.
• If it needs mixing, the liquid runs on its own clock. Look for the second date.
• If the box is gone, the bottle still has it — that is where the rule puts it.
• No date at all? Check the exemptions: homeopathic products, allergenic extracts labeled “No U.S. Standard of Potency,” investigational products, and the narrow OTC carve-out.
• Past the date, the strength question has no answer from the label. For anything where the strength matters, that is a pharmacist’s question — the same escalation the labeling rules themselves use when the label cannot answer.

What this page does not cover

What 21 CFR 211.137 requires, what 21 CFR 211.166 requires of the testing behind it, and where 21 CFR 201.17 requires the date to appear. It does not cover what happens to a specific drug after its date — the section requires data up to the date and says nothing beyond it, and the degradation rates of individual products are a stability-science question this page does not attempt. It does not cover veterinary products, which are governed elsewhere, or the separate rules for medical devices and for biologics. And it does not give medical advice: whether a particular expired product is right for a particular person is a question for a clinician or a pharmacist.